Disable cancer resistance with nanoparticles

Cancer nanoparticles are supposed to help drugs get into tumors. The harder problem is what happens after that. Many cancer cells just spit the drug back out. That escape route — multidrug resistance — is one of the main reasons chemotherapy works at first and then stops working. A team led by Eijiro Miyako at Tohoku University says it found a cleaner way around that trap: send in a nanoparticle that shuts down the pump first, then releases the chemo, then adds heat from a laser to finish the job. ### What resistance are they trying to beat? A lot of resistant tumors overexpress P-glycoprotein, or P-gp. Basically, it is a membrane pump that ejects anticancer drugs before the drugs can build up inside the cell. That means you can deliver chemotherapy to the tumor and still get a weak effect, because the cell is actively clearing the payload. ### Why hasn’t the obvious fix worked? The obvious fix is to give a P-gp inhibitor together with chemotherapy. (eurekalert.org) But turns out timing matters. If both arrive at once, the pump may still be working when the chemo first hits, so part of the dose gets lost. The whole idea in this paper is that resistance is not just a target problem — it is a sequence problem. ### What did they build? The group made porous amino-acid nanoparticles loaded with doxorubicin, a common chemotherapy drug. (eurekalert.org) They coated the particles with polydopamine and attached quinidine, which inhibits P-gp, through a pH-sensitive linker. So the nanoparticle is doing three jobs at once: targeted delivery, staged drug release, and photothermal heating when hit with near-infrared light. ### Why does the sequence matter so much? Think of a leaky bucket. (eurekalert.org) If you pour in water before patching the hole, you waste the water. Same here. The quinidine is meant to come off first in the acidic tumor environment, blunting the drug-efflux pump before doxorubicin is released. That gives the chemo a better chance to stay inside resistant cancer cells long enough to matter. ### Where does the laser come in? The polydopamine shell also converts near-infrared light into heat. (eurekalert.org) That gives the treatment a second kill mechanism — photothermal therapy — on top of chemotherapy. In the mouse experiments, that combined approach beat either strategy alone. Photothermal treatment by itself caused only temporary tumor shrinkage before the cancer came back, but the full three-part system drove complete regression. ### How strong were the mouse results? (eurekalert.org) In the reported drug-resistant tumor model, every mouse that got the nanoparticle-plus-laser treatment survived through the 40-day observation window. All comparison groups failed to reach day 40. The researchers also say they saw no detectable toxicity in normal tissues, which is a big part of the pitch here — not just stronger tumor control, but stronger control without obvious collateral damage in mice. ### So is this close to a human treatment? Not yet. This is still preclinical mouse work, published May 6, 2026 in the *Journal of Controlled Release* by Tengfei Wang, Nina Sang, Cécilia Ménard-Moyon, Eijiro Miyako, and Alberto Bianco. Mouse cures fail all the time when they hit the messier reality of human tumors, dosing, manufacturing, and safety testing. But the mechanism is the interesting part — the team is not just delivering more drug, it is reordering the attack. (phys.org) ### Bottom line? The real news is not “nanoparticles beat cancer.” It is narrower and more useful than that. This study shows a way to disable a common resistance pathway before chemotherapy lands, then stack heat on top. If that logic survives bigger animal studies and eventually human trials, it could turn some “chemo stopped working” tumors back into treatable ones. (eurekalert.org) (miragenews.com)